JPH05186357A - Absorption-inhibitory means for digested product of food/ beverage - Google Patents

Absorption-inhibitory means for digested product of food/ beverage

Info

Publication number
JPH05186357A
JPH05186357A JP3359568A JP35956891A JPH05186357A JP H05186357 A JPH05186357 A JP H05186357A JP 3359568 A JP3359568 A JP 3359568A JP 35956891 A JP35956891 A JP 35956891A JP H05186357 A JPH05186357 A JP H05186357A
Authority
JP
Japan
Prior art keywords
sodium polyacrylate
food
aqueous liquid
active ingredient
drink
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP3359568A
Other languages
Japanese (ja)
Inventor
Shigeo Ochi
智 繁 夫 越
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP3359568A priority Critical patent/JPH05186357A/en
Priority to CH3987/92A priority patent/CH684740A5/en
Priority to AU30455/92A priority patent/AU3045592A/en
Priority to FR929215947A priority patent/FR2685611B1/en
Priority to GB9227128A priority patent/GB2262888B/en
Priority to DE4244588A priority patent/DE4244588A1/de
Priority to CA002086566A priority patent/CA2086566A1/en
Publication of JPH05186357A publication Critical patent/JPH05186357A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/78Polymers containing oxygen of acrylic acid or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25Synthetic polymers, e.g. vinylic or acrylic polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

PURPOSE:To provide the subject means readily takeable during one's meal, containing, as active ingredient, sodium polyacrylate in an acidic aqueous liquid. CONSTITUTION:The objective means can be obtained by adding, as active ingredient, sodium polyacrylate to an acidic aqueous liquid (e.g. an aqueous solution of ascorbic acid or citric acid; fruit juice such as of lemon or orange). Specifically, 2-3g of sodium polyacrylate is dissolved in 100ml of an acidic liquid and the pH value of the resulting solution is adjusted to <=5. The amount to be taken is 0.05 to 0.1g/adult/day. This product gives activity even at a low level because it can be penetrated and dispersed throughout the foods taken in the stomach by taking the sodium polyacrylate in the form of solution. This means is also useful for obesity prevention, hepatic dysfunction improvement, hyperlipemia improvement, diabetics improvement, or constipation prevention.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は飲食物消化分解産物吸収
抑制手段、肥満防止手段、高脂血症改善手段、糖尿病改
善手段、便秘防止手段及び肝機能障害改善手段に関す
る。なお本明細書に於いて「飲食物消化分解産物」には
消化分解の直接の産物たる栄養分のほか、消化分解の間
接的産物たる代謝産物も含まれるものとする。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to means for suppressing absorption of digested and decomposed products of foods, means for preventing obesity, means for improving hyperlipidemia, means for improving diabetes, means for preventing constipation, and means for improving liver dysfunction. In the present specification, "digestion and degradation products of food and drink" include nutrients which are direct products of digestion and degradation, and metabolites which are indirect products of digestion and degradation.

【0002】[0002]

【従来の技術】曽ての食料難の時代、或いは今も飢餓に
苦しむ国々を除けば、栄養の採り過ぎの弊害は、人々に
とって常に克服し難いテーマであった。健康上、美容上
等多くの問題を惹き起こすことは、改めて説明するまで
もない。頭では理解していても、一番簡単確実な食事制
限が容易には実行できないからである。栄養の採り過ぎ
がもたらす諸症状には肥満、高脂血症、動脈硬化、心疾
患、糖尿病等所謂各種成人病、肝機能障害などがある。
この為、民間療法的には(多くは女性の肥満防止を目的
として)様々な手法が数限りなく提案され、実行されて
いる。また商業的なサービスとして行なわれているもの
も多い。しかし簡単に実行でき、しかも安全性高く、効
果確実という手法は出願人が知る限り、未だ出現してい
ないようである。一方医学的には、医薬品として例えば
欧米に於いて市販されているアンフェタミン、フェンフ
ラミン、ファセオラミンや、マジンドール等がある。し
かし、これらは何れも脳の視床下部の摂食中枢や満腹中
枢に直接、間接に作用するものである。この為、習慣
性、精神高揚、不眠、口渇等の副作用を伴う場合があ
り、また連服による効能の低下も見られる。このような
課題を解決すべく、本願発明者は、先に、凝集剤、例え
ばポリアクリル酸ソーダを水系腸溶性膜で被覆してなる
飲食物消化分解産物吸収抑制手段等を提案した(特開平
3−120227号公報)。これらは、腸内に於いて凝
集、架橋効果により消化分解産物のフロックを形成さ
せ、これにより腸管内吸収を抑制する、しかも効用効果
においても顕著で極めて高い安全性を有する特長を持つ
ものである。
2. Description of the Related Art Except in times of complete food shortage or in countries that are still suffering from hunger, the harmful effects of excessive nutrition have always been difficult for people to overcome. It is needless to explain again that it causes many problems such as health and beauty. This is because even if you understand it in your head, the simplest and most reliable dietary control is not easily implemented. Various symptoms caused by over-nutrition include obesity, hyperlipidemia, arteriosclerosis, heart disease, so-called various adult diseases such as diabetes, and liver dysfunction.
Therefore, various methods (mostly for the purpose of preventing obesity of women) have been proposed and implemented as folk remedies. Many are also offered as commercial services. However, as far as the applicant knows, it seems that a method that can be easily executed, is highly safe, and has a positive effect has not yet appeared. On the other hand, medically, for example, amphetamine, fenflamin, phaseolamine, mazindol and the like which are commercially available in Europe and America are available as pharmaceuticals. However, all of these act directly or indirectly on the feeding and satiety centers of the hypothalamus of the brain. For this reason, side effects such as habit, spiritual uplifting, insomnia, and dry mouth may be accompanied, and the efficacy may be reduced by continuous administration. In order to solve such a problem, the inventor of the present application has previously proposed a means for suppressing absorption of food and drink digestive degradation products, which is obtained by coating a flocculant, for example, sodium polyacrylate with an aqueous enteric film. 3-120227 publication). These are characterized in that they form flocs of digestive degradation products due to aggregation and cross-linking effects in the intestine, thereby suppressing absorption in the intestinal tract, and have remarkable utility effects and extremely high safety. ..

【0003】[0003]

【発明が解決しようとする課題】ところで何事もそうで
あるが、日課的なことは日常生活の中で自然のうちに実
行できるのが最も望ましい。三日坊主の言葉にもある通
り、構えて何かをすると言うのでは長続きしないからで
ある。上記飲食物消化分解産物吸収抑制手段の摂取につ
いても同じで、毎日の食生活の中で自然に実行されるこ
とが好ましい。その為の一般的形は、健康飲料的形態、
即ち「飲み物状(飲料化)」である。顆粒や錠剤ではど
うしても医薬品というイメージが強く、公衆中や、食事
をしながら摂取するということも難しいものである。ま
た体裁は兎も角、顆粒や錠剤では現実に食物と一緒に口
に入れて噛み砕くことなど出来るものではない。どうし
ても食後改めて、ということになる。特に人と一緒に食
事をした場合など、後でということになると、つい忘れ
てしまうことになり易い。飲み物状であればそのような
ことは起こらない。水、或いは汁物やお茶、ビールやジ
ュース類等を飲むが如くこれを食事中に手軽に摂取する
ことができるからである。
By the way, as with anything, it is most desirable that daily routines can be carried out naturally in daily life. This is because it is not long-lasting to say that you do something by holding it up, as the words of the Sankabozu. The same applies to the intake of the above-mentioned means for suppressing the absorption of digested and decomposed products of food and drink, and it is preferable that the intake is carried out naturally in the daily diet. The general form for that is a healthy drink form,
That is, it is a "drink form". Granules and tablets have a strong image of medicines, and it is difficult to take them in the public or while eating. In addition, the appearance of rabbits, horns, granules and tablets cannot be put into the mouth together with food and chewed. It means that we should try again after eating. Especially when eating with people, it is easy to forget about it later. If it is a drink, it will not happen. This is because it can be easily ingested during meals like drinking water, soup, tea, beer or juices.

【0004】しかし従来の凝集剤、特に好適な凝集剤で
あるポリアクリル酸ソーダは、増粘剤として食品への添
加が認められていることからも明らかなように、極く少
量を水に加えただけでも強い粘性を示す。これを直接口
腔内に含んだ場合口中至る所にこれが粘着し、その不快
たること夥しく、その不快感は長時間(通常1時間前
後)持続するも尚消滅しない場合もある。この為、従来
は飲料的形態では飲食物消化分解産物除去手段等を実現
することは出来なかった。本発明はこの課題を更に検討
し、その効用効果を高める為になされたもので、その目
的とするところは、飲み物として食事中にも飲用可能な
飲食物消化分解産物吸収抑制手段を提供することにあ
り、併せてこの様な吸収抑制効果を利用した肥満防止手
段、高脂血症改善手段、糖尿病改善手段、便秘防止手段
及び肝機能障害改善手段を提供することにある。
However, conventional coagulants, especially polyacrylic acid soda, which is a suitable coagulant, are added to foods in a very small amount, as is clear from the fact that it is recognized as a thickener. It shows a strong viscosity even if it is used alone. When it is directly contained in the oral cavity, it sticks all over the mouth, which is uncomfortable, and the discomfort lasts for a long time (usually around 1 hour) but may not disappear yet. For this reason, conventionally, it has not been possible to realize a means for removing digested and decomposed products of food and drink in a drinkable form. The present invention has been made in order to further study this problem and to enhance its effect, and an object of the present invention is to provide a means for suppressing absorption of digested and decomposed products of food and drink which can be drunk during meals as a drink. In addition, there is also provided an obesity preventing means, hyperlipidemia improving means, diabetes improving means, constipation preventing means, and liver dysfunction improving means utilizing such absorption suppressing effect.

【0005】[0005]

【課題を解決するための手段】上記目的達成のため本発
明飲食物消化分解産物吸収抑制手段は酸性を呈する水性
液体中に有効成分としてポリアクリル酸ソーダを含有す
ることを特徴とする。同じく本発明肥満防止手段、高脂
血症改善手段、糖尿病改善手段、便秘防止手段及び肝機
能障害改善手段も、酸性を呈する水性液体中に有効成分
としてポリアクリル酸ソーダを含有することを特徴とす
る。なおこれら飲食物消化分解産物吸収抑制手段、肥満
防止手段、高脂血症改善手段、糖尿病改善手段、便秘防
止手段及び肝機能障害改善手段を併せて「本発明飲用手
段」と称することとする。
Means for Solving the Problems In order to achieve the above object, the means for inhibiting absorption of digested and decomposed products of food and drink according to the present invention is characterized by containing sodium polyacrylate as an active ingredient in an acidic aqueous liquid. Similarly, the present invention means for preventing obesity, means for improving hyperlipidemia, means for improving diabetes, means for preventing constipation and means for improving liver dysfunction also contain sodium polyacrylate as an active ingredient in an acidic aqueous liquid. To do. The means for suppressing the absorption of digested and decomposed products of food and drink, the means for preventing obesity, the means for improving hyperlipidemia, the means for improving diabetes, the means for preventing constipation, and the means for improving liver dysfunction will be collectively referred to as the "drinking means of the present invention".

【0006】酸性を呈する水性液体は、酸性でヒト、動
物飲用可能なものであれば何でも良い。化学的、工業的
に製造された特定の成分を水に溶解したものであっても
良いし、食品或いは飲料として使用されているもので酸
性を呈するものであっても良い。例えば一般的にアスコ
ルビン酸、クエン酸、酢酸などの水溶液があり、また各
種の食酢を希釈したもの、レモン、オレンジ等の柑橘類
の果汁やジュースなどがある。酸性度はpH5以下、好
ましくはpH2.5〜3.5とする。この酸性度にすると
酸性液100ミリリットルに対し、ポリアクリル酸ソー
ダ2〜3グラムが溶解し、なお飲用として十分な流動性
が保持される(粘度計による測定値約0.3〜0.6ポァ
ズ)。
[0006] The acidic aqueous liquid may be any acidic liquid that can be drunk by humans and animals. It may be a chemically or industrially produced specific component dissolved in water, or it may be one used as a food or beverage and exhibiting acidity. For example, generally, there are aqueous solutions of ascorbic acid, citric acid, acetic acid, etc., and those obtained by diluting various types of vinegar, and juices and juices of citrus fruits such as lemon and orange. The acidity is pH 5 or less, preferably pH 2.5 to 3.5. At this acidity, 2-3 g of sodium polyacrylate is dissolved in 100 ml of the acid solution, and the fluidity is sufficient for drinking (measured by a viscometer is about 0.3-0.6 poise). ).

【0007】摂取量は後述の実施例に示す通り、1日当
り成人で通常の場合0.05〜0.1グラム程度で効用効
果があると思料される。従って仮に100ミリリットル
当り2〜3グラムの濃度とした場合、1日僅か1.7〜
5.0ミリリットル飲用すれば十分ということになる。
(又、これを原液として更に希釈して飲用に供すること
は可能であることは云うまでもないことである。)極端
な例を挙げたが、要は本発明に依ればそれ程飲み物とし
て好適な飲用手段が実現できると言うことである。実施
に当っては、このような高濃度のものを僅か摂取する形
態と、飲み物としてある程度満足のいく量の低濃度のも
のを摂取する二通りの形態が考えられる。飲用を更に進
めれば、例えば蜂蜜レモンの如き味付を為し、飲料その
ものとしての実施も好ましい形態である。後述する実施
例では、水100ミリリットル当りアスコルビン酸10
00ミリグラムの水溶液を用いた。このときのpHは約
2.8で、食味は酸味を感ずる程度であり、甘味を少々
付加したところ、所謂スポーツドリンク風の清涼感溢れ
る食味となり、誠に好適であった。
[0007] As will be shown in the Examples below, the intake amount is considered to be effective for adults, usually about 0.05 to 0.1 gram per day. Therefore, assuming that the concentration is 2-3 grams per 100 milliliters, the daily concentration is only 1.7-
Drinking 5.0 milliliters is enough.
(It goes without saying that it is possible to further dilute this as a stock solution and to use it for drinking.) Although an extreme example was given, the point is that the present invention is suitable as a drink. It means that various drinking means can be realized. There are two modes of implementation, one is ingesting a small amount of such a high concentration and the other is ingesting a low concentration of a certain amount of a drink as a drink. If the drinking is further advanced, it is also preferable that the beverage is seasoned like honey lemon and the beverage itself is used. In the examples described later, ascorbic acid 10 per 100 ml of water
00 milligrams of aqueous solution was used. At this time, the pH was about 2.8, the taste was such that the taste was sour, and when a little sweetness was added, a so-called sports drink-like taste with a refreshing feeling was obtained, which was very suitable.

【0008】[0008]

【作用】胃液は言うまでもなく強酸性を呈す。従って胃
の内部、特に胃第1相及び第2相(噴門部乃至胃体部)
に於いて飲用前と同様の酸性状態が維持される。従って
ポリアクリル酸ソーダは、溶液状態で食物中に分散混合
されることになる。先に飲食物消化分解産物吸収抑制手
段等を出願した際、発明者はこれらポリアクリル酸ソー
ダ等の凝集剤を水系腸溶性膜で覆うこととしたり、或い
は腸溶性カプセル内に封入したものを服用し、胃中では
顆粒または錠剤、カプセル剤(硬カプセル剤、軟カプセ
ル剤)等の形態で食物中に分散混合されるよう企図して
いた。本発明飲用手段の場合、既に飲用前にこのポリア
クリル酸ソーダが水性液体中に溶液として存在してお
り、胃中でもこの状態が維持されながら飲食物中に混合
分散され、強力な胃の揉捏作用により食物中細部へ更に
浸潤する結果、凝集効果が一段と高められ、同じ摂取量
であれば効用効果が大となり、同じ効用効果を期待する
場合本発明飲用手段摂取量を大幅に削減させることが出
来る。胃に於ける効果だけでは無いとも思料されるが、
前記従来の飲食物消化分解産物吸収抑制手段等に比べ、
本発明飲用手段は約1/10〜1/40量の摂取でほぼ
同じ効果が見られた。
[Action] Needless to say, gastric juice is strongly acidic. Therefore, inside the stomach, especially in the first and second phases of the stomach (cardiac or gastric body)
, The same acidic condition as before drinking is maintained. Therefore, sodium polyacrylate is dispersed and mixed in food in a solution state. When applying for a means for suppressing the absorption of digested and decomposed products of food and drink, etc., the inventor decided to cover these aggregating agents such as sodium polyacrylate with an aqueous enteric film, or take those encapsulated in an enteric capsule. However, in the stomach, it was intended to be dispersed and mixed in food in the form of granules or tablets, capsules (hard capsules, soft capsules) and the like. In the case of the drinking means of the present invention, this sodium polyacrylate is already present as a solution in an aqueous liquid before drinking, and it is mixed and dispersed in food and drink while maintaining this state even in the stomach, giving a strong stomach kneading. As a result of further infiltrating into the details in the food by the action, the cohesive effect is further enhanced, and the effect is large at the same intake amount, and when the same effect is expected, the intake amount of the present invention can be drastically reduced. I can. It is thought that it is not only the effect on the stomach,
Compared with the conventional means for suppressing the absorption of digested and decomposed products of food and drink,
With the drinking means of the present invention, almost the same effect was observed at an intake of about 1/10 to 1/40.

【0009】胃第3相(幽門部)から小腸上部(十二指
腸から空腸)に至り食物の消化分解は更に進行し分子状
にまで消化分解されながら同時に吸収が行なわれる。該
部分及びそれ以降に於いて、ポリアクリル酸ソーダによ
る飲食物消化分解産物の凝集が行なわれる。既にポリア
クリル酸ソーダが溶液として飲食物消化分解産物内に分
散されているので、より有効に飲食物消化分解産物の凝
集塊が形成される。先願の飲食物消化分解産物除去手段
等も胃第3相から小腸上部に至り外周を覆っていた水系
腸溶性膜が溶解し、その部分以降飲食物消化分解産物を
凝集させるが、時として胃中においてポリアクリル酸ソ
ーダ自身が大きな集塊状態となり目的に必要な食物との
分散混合が行われず、その結果十分なフロック形成に至
らなず、効用効果の低下につながることがあった。これ
は水系腸溶性膜溶解後、錠剤や細粒や顆粒が十分に分散
する以前に外側から特に水分等が先に浸潤し、ポリアク
リル酸ソーダを中心とする凝集塊を生じ分散されないま
ま腸管を通過するためと思料される。何れにしろ本発明
では液状にした結果、しかも攪拌効果の高い胃に於いて
同じ酸性状態が保たれることとなった結果、従来より遥
かに飲食物中、及び消化分解産物中の細部にまで分散混
合されることとなり、凝集効果効率及び効用効果が一段
と高められた。
From the third phase of the stomach (pylorus) to the upper small intestine (duodenum to jejunum), the digestive decomposition of food further progresses, and it is simultaneously absorbed while being digested into molecular form. In the portion and thereafter, aggregation of food and drink digestion decomposition products with sodium polyacrylate is performed. Since the sodium polyacrylate is already dispersed as a solution in the food and drink digestion decomposition product, the aggregate of the food and drink digestion decomposition product is more effectively formed. The means for removing food digestion degradation products of the prior application also dissolves the water-based enteric-coated film covering the outer periphery from the gastric phase 3 to the upper part of the small intestine, and after that portion, the food digestion decomposition products are aggregated. In the inside, the sodium polyacrylate itself became a large agglomerated state and was not dispersed and mixed with the food necessary for the purpose. As a result, sufficient floc formation could not be achieved, leading to a decrease in the effect of the effect. This is because after the water-based enteric film is dissolved, before the tablets, fine particles, and granules are sufficiently dispersed, especially water and the like infiltrate from the outside first, and agglomerates centering on sodium polyacrylate are formed to cause the intestinal tract to remain undispersed. It is thought to pass. In any case, in the present invention, as a result of being liquefied, and as a result that the same acidic state is maintained in the stomach with a high stirring effect, it is far more detailed than before in foods and drinks and digestive degradation products. Since they are dispersed and mixed, the efficiency of cohesion and the effect of utility are further enhanced.

【0010】凝集物は飲食物消化分解産物とポリアクリ
ル酸ソーダが架橋を中心とする集合体、フロック(塊
状)を形成し、表面がのり状、或いはとろみ状(片栗溶
解状)を呈し、小腸、中でも主たる吸収部位である空腸
を通過する際この凝集物は腸壁からの吸収が抑制され
る。従って飲食物消化分解産物は、本発明飲用手段の投
与量に応じた所定量の吸収が抑制され、糞便として体外
に排出されることになる。凝集物には脂質、炭水化物、
等を始め飲食物の消化分解により生ずる各種産物(栄養
素等)が含まれる。従ってこれらの吸収を抑制する本発
明飲用手段は肥満防止手段としても作用する。また凝集
物の表面がのり状、或いはとろみ状(片栗溶解状)であ
り、これが食物残渣或いは糞便中に混合される為、円滑
に腸内を通過する。腸管膜の障害を生じることはなく、
寧ろ排便促進効果が明確に見られ、便秘防止手段として
も有効に作用する。また、実施例による結果成績からも
血中脂質類及びロイシンアミノペプチターゼ、コリンエ
ステラーゼ等、肝機能障害の指標項目の改善効果も見ら
れ、このことからも肝機能障害の改善手段としても期待
されるものである。
The agglomerates form flocs (lumps) in which the digestion and decomposition products of foods and drinks and sodium polyacrylate are mainly cross-links, and the surface is paste-like or thick (dissolving kataguri), and the small intestine. Above all, when passing through the jejunum, which is the main absorption site, absorption of this aggregate from the intestinal wall is suppressed. Therefore, the digested and decomposed products of food and drink are suppressed from being absorbed in a predetermined amount according to the dose of the drinking means of the present invention, and are excreted outside the body as feces. Aggregates include lipids, carbohydrates,
Etc., and various products (nutrients, etc.) produced by digestion and decomposition of food and drink are included. Therefore, the drinking means of the present invention that suppresses these absorptions also acts as an obesity preventing means. In addition, the surface of the aggregate is paste-like or thick (dissolved in kataguri), and this is mixed with food residue or feces, so that it smoothly passes through the intestine. Without causing damage to the intestinal membrane,
On the contrary, the defecation promoting effect is clearly seen, and it also works effectively as a constipation preventing means. Further, from the results of the examples, blood lipids and leucine aminopeptidase, cholinesterase, and the like are also shown to have an improving effect on index items of liver dysfunction, which is also expected as a means for improving hepatic dysfunction. It is a thing.

【0011】[0011]

【実施例】以下に実施例を記述する。これらは本発明を
より詳細に説明するためのものであり、本発明がこれに
限定されるものではない。 [飲用手段の調製]水に電解質を加え若干調味した所謂
スポーツドリンク風の水性液体に100ミリリットル当
り1000ミリグラムのアスコルビン酸を溶解して酸性
水性液体とした。この液体の酸性度はpH2.8で、食
味も酸味を感ずると言う程度とした。この液体に100
ミリリットル当り0.05グラムのポリアクリル酸ソー
ダを溶解し飲用手段とした。ポリアクリル酸ソーダ添加
前と添加後に於いて、粘度或いは流動性に目立った違い
は見られなかった(粘度約0.02ポァズ 摂氏20度
下)。
EXAMPLES Examples will be described below. These are for explaining the present invention in more detail, but the present invention is not limited thereto. [Preparation of Drinking Means] An acidic aqueous liquid was prepared by dissolving 1000 mg of ascorbic acid per 100 ml in a so-called sports drink-like aqueous liquid prepared by adding an electrolyte to water. The acidity of this liquid was pH 2.8, and the taste was such that the taste was not sour. 100 to this liquid
0.05 g of sodium polyacrylate was dissolved per milliliter and used as a drinking means. No significant difference in viscosity or fluidity was observed before and after the addition of sodium polyacrylate (viscosity: about 0.02 poise, below 20 degrees Celsius).

【0012】[試験例]試験条件は以下の通りである。 被験者 性別 年齢 身長 初期体重 健康状態 便通 職種 A 女 56 150 75.0Kg 異常なし 便秘 看護婦 B 女 55 156 82.7Kg 異常なし 便秘 主婦 C 女 57 160 88.5Kg 異常なし 便秘 主婦 D 女 56 152 55.2Kg 異常なし 便秘 主婦 E 男 55 170 78.8Kg 異常なし 便秘 会社員 F 女 43 162 77.5Kg 異常なし 便秘 看護婦 試験期間 平成3年7月〜10月の4ヵ月間 摂取態様 昼食時及び夕食時 1回100ミリリット
ルを食事中に摂取(1日当りポリアクリル酸ソーダ約
0.1グラム相当)。なお食事内容については特に条件
を付けず、各被験者とも人のそれ迄の食生活スタイルを
その儘維持した。 データ採取方法 被験者全員について試験開始前及び開始後1ヵ月毎に、
血液一般検査及び生化学検査約40項目の測定を実施し
継続的に変化を観察した。
[Test Example] The test conditions are as follows. Subject Gender Age Height Initial weight Health condition Feces A Type of job A Woman 56 150 75.0Kg No abnormalities Constipation Nurse B Women 55 156 82.7Kg No abnormalities Constipation Housewife C Woman 57 160 88.5Kg No abnormalities Constipation Housewife D Woman 56 55.152 2Kg No abnormalities Constipation Housewife E Male 55 170 170 78.8Kg No abnormalities Constipation Office worker F Woman 43 162 162 77.5Kg No abnormalities Constipation Nurse Exam period 4 months from July to October 1991 Ingestion mode Lunch and dinner Ingest 100 ml once in a meal (equivalent to about 0.1 g of sodium polyacrylate per day). In addition, no particular condition was attached to the content of the meal, and each subject maintained the eating habits of the person until then. Data collection method For all subjects, before the start of the test and every month after the start,
Blood general test and biochemical test About 40 items were measured and changes were observed continuously.

【0013】測定の結果、特に血清中のロイシンアミノ
ペプチターゼ、コリンエステラーゼ、トリグリセライ
ド、総コレステロール、ベータリポ蛋白等に改善効果が
見られた。そのデータを図1〜図5に示す(各折れ線と
被験者との対応は各図に示す)。被験者全員について、
血清中の上記項目の各成分の低下改善が認められ、飲用
の効用効果が出現した。尚総コレステロール値は本来3
ヵ月〜半年或いは1年と経過し徐々に低下するものであ
るが、今回の試験では被験者6人中4人(ABDF)の
それが明確に減少しており、この点でも効用効果が証明
された。体重の変化は次の通りであった。 被験者 初期体重 4ヵ月後 減少量 A 75.0Kg 71.3Kg 3.7Kg B 82.7Kg 78.4Kg 4.3Kg C 88.5Kg 86.6Kg 1.9Kg D 55.2Kg 52.8Kg 2.4Kg E 78.8Kg 75.3Kg 3.5Kg F 77.5Kg 74.2Kg 3.3Kg
As a result of the measurement, the improving effect was observed especially in serum leucine aminopeptidase, cholinesterase, triglyceride, total cholesterol, beta lipoprotein and the like. The data are shown in FIGS. 1 to 5 (correspondence between each broken line and the subject is shown in each figure). For all subjects,
The reduction and improvement of each component of the above items in serum was observed, and the effect of drinking appeared. The total cholesterol level is originally 3
Although it gradually decreases over a period of one month to half a year or one year, it was clearly reduced in 4 out of 6 subjects (ABDF) in this study, and a utility effect was also proved in this respect. .. The changes in body weight were as follows. Subject Initial weight after 4 months Reduction A 75.0Kg 71.3Kg 3.7Kg B 82.7Kg 78.4Kg 4.3Kg C 88.5Kg 86.6Kg 1.9Kg D 55.2Kg 52.8Kg 2.4Kg E 78 8kg 75.3kg 3.5kg F 77.5kg 74.2kg 3.3kg

【0014】また排便態度(回数、便量、便質、排便状
態等、)及び実施例手段の飲用後の自覚諸変化を毎日4
ヵ月間記載記録した。試験開始前は全員便秘常習であっ
た。摂取開始後3日〜1週間経過後から、全員が1日1
〜3回の排便を見るようになった。便の固さ、便質とも
良好であった。更に便色が綺麗な胆汁色へと変化するこ
とも観察された。このことは本発明飲用手段が胆汁、胆
汁酸等を凝集させ体外に排出することを意味している。
胆汁酸は主に血中脂質類を中心に生成され空腸での再吸
収が行われるが、それが阻害されることによりその分、
体内の脂肪の代謝が促進される。この点で本発明飲用手
段は高脂血症の改善、更に肝機能障害の改善用等として
の効用効果も有している。
Also, daily changes in defecation attitude (number of times, amount of stool, stool quality, defecation state, etc.) and various consciousness changes after the use of the means of the embodiment are taken every day.
Recorded for a month. Before the test started, all were constipation habits. 3 days to 1 week after the start of intake
I started seeing 3 defecations. The hardness and quality of the stool were good. It was also observed that the stool color changed to a beautiful bile color. This means that the drinking means of the present invention aggregates bile, bile acid and the like and discharges them out of the body.
Bile acids are mainly produced mainly in blood lipids and are reabsorbed in the jejunum.
The metabolism of fat in the body is promoted. In this respect, the drinking means of the present invention has an effect of improving hyperlipidemia and further improving liver dysfunction.

【0015】なお本発明飲用手段に食物繊維やキチン、
キトサン等を混合しても良い。効用効果が一層高められ
る。
In the drinking means of the present invention, dietary fiber or chitin,
You may mix chitosan etc. The utility effect is further enhanced.

【0016】[0016]

【発明の効果】以上説明したように、本発明飲用手段は
酸性を呈する水性液体中に有効成分としてポリアクリル
酸ソーダを含有し、通常の飲料と同様の性状を呈する。
従って従来のものと異なり、食事中に気軽に摂取するこ
とが容易となった。また液状化により胃中に於いて食物
中細部に浸透分散が行なわれるようになった結果、従来
のものに比し一段と少量で、同じ効用が発揮される。更
に従来のものはポリアクリル酸ソーダの粉末或いは顆粒
に水系腸溶性膜を被覆する必要があった。この作業はか
なり煩雑である。水系腸溶性膜の素材、例えばヒドロキ
シプロピルメチルセルロースアセテートサクシネート
は、アセトンなどの引火性、中毒性の高い溶剤でなけれ
ば溶解せず、これをポリアクリル酸ソーダの顆粒に吹き
付けて乾燥するのであるが、これにはかなりの設備と工
数を要する。この為コスト高になることは否めなかっ
た。本発明飲用手段は酸性を呈する水性液体中にポリア
クリル酸ソーダを投入攪拌するだけで足り、極めて容易
に且つ安価に製造することが出来る。
As described above, the drinking means of the present invention contains sodium polyacrylate as an active ingredient in an acidic aqueous liquid, and exhibits the same properties as ordinary beverages.
Therefore, unlike the conventional ones, it is easy to take during meals. In addition, as a result of liquefaction, permeation and dispersion of fine details in food in the stomach are performed, and as a result, the same effect is exhibited in a much smaller amount than the conventional one. Further, in the prior art, it was necessary to coat the powder or granules of sodium polyacrylate with an aqueous enteric film. This task is quite complicated. The material for the water-based enteric film, for example, hydroxypropylmethylcellulose acetate succinate, is insoluble in a flammable and highly toxic solvent such as acetone, and is sprayed onto sodium polyacrylate granules for drying. , This requires considerable equipment and man-hours. Therefore, it cannot be denied that the cost will increase. The drinking means of the present invention only requires the addition and stirring of sodium polyacrylate into an aqueous liquid exhibiting acidity, and can be manufactured extremely easily and inexpensively.

【図面の簡単な説明】[Brief description of drawings]

【図1】本発明飲用手段の服用に係る血清ロイシンアミ
ノペプチターゼの変化状態を示す線図。
FIG. 1 is a diagram showing the altered state of serum leucine aminopeptidase upon taking the drinking means of the present invention.

【図2】本発明飲用手段の服用に係る血清コリンエステ
ラーゼの変化状態を示す線図。
FIG. 2 is a diagram showing the state of changes in serum cholinesterase associated with the administration of the drinking means of the present invention.

【図3】本発明飲用手段の服用に係る血清トリグリセラ
イドの変化状態を示す線図。
FIG. 3 is a diagram showing a change state of serum triglyceride upon taking the drinking means of the present invention.

【図4】本発明飲用手段の服用に係る血清総コレステロ
ールの変化状態を示す線図。
FIG. 4 is a diagram showing a change state of serum total cholesterol associated with taking the drinking means of the present invention.

【図5】本発明飲用手段の服用に係る血清ベータリポ蛋
白の変化状態を示す線図。
FIG. 5 is a diagram showing changes in serum beta lipoprotein associated with taking the drinking means of the present invention.

フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 31/78 ADP Continuation of the front page (51) Int.Cl. 5 Identification code Office reference number FI technical display area A61K 31/78 ADP

Claims (6)

【特許請求の範囲】[Claims] 【請求項1】 酸性を呈する水性液体中に有効成分とし
てポリアクリル酸ソーダを含有することを特徴とする飲
食物消化分解産物吸収抑制手段。
1. A means for suppressing absorption of digested and decomposed products of food and drink, comprising sodium polyacrylate as an active ingredient in an acidic aqueous liquid.
【請求項2】 酸性を呈する水性液体中に有効成分とし
てポリアクリル酸ソーダを含有することを特徴とする肥
満防止手段。
2. A means for preventing obesity, which comprises sodium polyacrylate as an active ingredient in an acidic aqueous liquid.
【請求項3】 酸性を呈する水性液体中に有効成分とし
てポリアクリル酸ソーダを含有することを特徴とする高
脂血症改善手段。
3. A means for improving hyperlipidemia, which comprises sodium polyacrylate as an active ingredient in an acidic aqueous liquid.
【請求項4】 酸性を呈する水性液体中に有効成分とし
てポリアクリル酸ソーダを含有することを特徴とする糖
尿病改善手段。
4. A means for improving diabetes, which comprises sodium polyacrylate as an active ingredient in an acidic aqueous liquid.
【請求項5】 酸性を呈する水性液体中に有効成分とし
てポリアクリル酸ソーダを含有することを特徴とする便
秘防止手段。
5. A constipation-preventing means comprising sodium polyacrylate as an active ingredient in an acidic aqueous liquid.
【請求項6】 酸性を呈する水性液体中に有効成分とし
てポリアクリル酸ソーダを含有することを特徴とする肝
機能障害改善手段。
6. A means for improving liver dysfunction, which comprises sodium polyacrylate as an active ingredient in an acidic aqueous liquid.
JP3359568A 1991-12-31 1991-12-31 Absorption-inhibitory means for digested product of food/ beverage Pending JPH05186357A (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP3359568A JPH05186357A (en) 1991-12-31 1991-12-31 Absorption-inhibitory means for digested product of food/ beverage
CH3987/92A CH684740A5 (en) 1991-12-31 1992-12-30 Absorption inhibitor for Digestive and decomposition products of food and drink.
AU30455/92A AU3045592A (en) 1991-12-31 1992-12-30 Inhibitor for absorption of digested and decomposed products of food and drink
FR929215947A FR2685611B1 (en) 1991-12-31 1992-12-30 INHIBITOR OF ABSORPTION OF DIGERATED AND DECOMPOSED PRODUCTS OF FOODS AND BEVERAGES.
GB9227128A GB2262888B (en) 1991-12-31 1992-12-30 Inhibitor for absorption of digested and decomposed products of food and drink
DE4244588A DE4244588A1 (en) 1991-12-31 1992-12-31
CA002086566A CA2086566A1 (en) 1991-12-31 1992-12-31 Inhibitor for absorption of digested and decomposed products of food and drink

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP3359568A JPH05186357A (en) 1991-12-31 1991-12-31 Absorption-inhibitory means for digested product of food/ beverage

Publications (1)

Publication Number Publication Date
JPH05186357A true JPH05186357A (en) 1993-07-27

Family

ID=18465171

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3359568A Pending JPH05186357A (en) 1991-12-31 1991-12-31 Absorption-inhibitory means for digested product of food/ beverage

Country Status (7)

Country Link
JP (1) JPH05186357A (en)
AU (1) AU3045592A (en)
CA (1) CA2086566A1 (en)
CH (1) CH684740A5 (en)
DE (1) DE4244588A1 (en)
FR (1) FR2685611B1 (en)
GB (1) GB2262888B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522082A (en) * 2003-04-05 2006-09-28 アストラゼネカ アクチボラグ Use of an IBAT inhibitor for the treatment or prevention of constipation

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
ATE349214T1 (en) 2001-09-08 2007-01-15 Astrazeneca Ab BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH AN INHIBITING EFFECT ON ACID TRANSPORT IN THE BILITIES FOR THE TREATMENT OF HYPERLIPIDAEMIA
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
AU2008202120B2 (en) * 2003-04-05 2009-12-17 Albireo Ab Use of an IBAT inhibitor for the treatment of prophylaxis of constipation
RU2591188C2 (en) 2010-11-08 2016-07-10 Альбирео Аб Ibat inhibitor for treating hepatic disorders
JO3301B1 (en) 2013-04-26 2018-09-16 Albireo Ab Crystal modifications of elobixibat
CN106659726A (en) 2014-06-25 2017-05-10 Ea制药株式会社 Solid preparation, and method for preventing or reducing discoloration thereof
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CN111032019B (en) 2017-08-09 2022-07-05 阿尔比里奥公司 Cholestyramine granules, oral cholestyramine preparation and application thereof
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
BR112020024479A2 (en) 2018-06-20 2021-03-02 Albireo Ab crystalline hydrate, odevixibat crystalline modifications, mixed odevixibat solvate, use of odevixibat crystalline modification, process for the preparation of odevixibat crystalline modification, and pharmaceutical composition
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114761080B (en) 2019-12-04 2024-07-23 阿尔比里奥公司 Benzothiazepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
CR20220315A (en) 2019-12-04 2022-10-26 Albireo Ab BENZOTI(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS
ES2972045T3 (en) 2019-12-04 2024-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158184A1 (en) 2019-12-04 2021-08-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
JP2023537285A (en) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ Benzothia(di)azepine compounds and their use as bile acid modulators
KR20230106651A (en) 2020-11-12 2023-07-13 알비레오 에이비 Odevixivat for the treatment of progressive familial intrahepatic cholestasis (PFIC)
AU2021390172A1 (en) 2020-12-04 2023-06-22 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2221139B1 (en) * 1973-03-13 1978-03-24 Nippon Kayaku Kk
DE3307816A1 (en) * 1983-03-02 1984-09-06 Schering AG, 1000 Berlin und 4709 Bergkamen PROSTAGLANDINE-CONTAINING PHARMACEUTICAL PREPARATION AND ITS PRODUCTION
GB8419245D0 (en) * 1984-07-27 1984-08-30 Reckitt & Colmann Prod Ltd Medicinal compositions
JPS61172815A (en) * 1985-01-28 1986-08-04 Toshiyuki Nakajima Lubricant
GB8817015D0 (en) * 1988-07-16 1988-08-17 Reckitt & Colmann Prod Ltd Method of treatment
GB8910076D0 (en) * 1989-05-03 1989-06-21 Thackray C F Ltd Sterilisable lubricant
JPH03120227A (en) * 1989-10-02 1991-05-22 Shigeo Ochi Agent for absorbing and suppressing digested and degraded product of food and drink

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522082A (en) * 2003-04-05 2006-09-28 アストラゼネカ アクチボラグ Use of an IBAT inhibitor for the treatment or prevention of constipation
JP2011173925A (en) * 2003-04-05 2011-09-08 Albireo Ab Use of ibat inhibitor for treatment of constipation
JP4870552B2 (en) * 2003-04-05 2012-02-08 アルビレオ・アクチボラグ Use of an IBAT inhibitor for the treatment or prevention of constipation

Also Published As

Publication number Publication date
AU3045592A (en) 1993-07-08
FR2685611A1 (en) 1993-07-02
GB9227128D0 (en) 1993-02-24
FR2685611B1 (en) 1994-06-10
GB2262888A (en) 1993-07-07
CA2086566A1 (en) 1993-07-01
CH684740A5 (en) 1994-12-15
GB2262888B (en) 1996-07-24
DE4244588A1 (en) 1993-07-15

Similar Documents

Publication Publication Date Title
JPH05186357A (en) Absorption-inhibitory means for digested product of food/ beverage
JP3850891B2 (en) Composition having a laxative effect
JP3647877B2 (en) Acid food neutralization
US20100316768A1 (en) Nutritionally Fortified Liquid Composition With Added Value Delivery Systems/Elements/Additives
JP2983503B2 (en) Iron-calcium mineral supplement with high bioavailability
TW200812503A (en) Compositions, methods and kits for enhancing weight loss while inhibiting loss of lean body mass
CN103209684A (en) Aqueous drug delivery system comprising off - flavor masking agent
AU2015253178B2 (en) Foods, systems, methods, and kits for providing electrolyte replacement
JPH05255097A (en) Liquid composition
JP5414995B2 (en) Acidic urine-improving food and drink and pharmaceutical composition for oral administration comprising fucoidan as an active ingredient
Smith et al. Dietary concerns associated with the use of medications
JPH0272843A (en) Mineral supplement containing sugar alcohol
JPH0614746A (en) Health beverage
JP3489095B2 (en) Health foods and beverages
JP2000189109A (en) Liquid food
JP3884611B2 (en) Improving agent for impulsive disease
JP2002193797A (en) Composition for ameliorating insulin resistance
JPH10306028A (en) Drug for controlling intestinal function by lipid digestive absorbent inhibition
US20020137729A1 (en) Combinations of psyllium and chitosan for synergistic adsorption of triglyceride
WO2001091730A1 (en) Mineral supplement
JPH06507393A (en) Pharmaceutical compositions of water-soluble high viscosity grade cellulose ethers and their uses
US20050214362A1 (en) Appetite suppressant
US10639328B1 (en) Compositions and methods for reducing hyperglycemia and treating diabetes
JP4435882B2 (en) Alcohol absorption inhibiting composition
Kemp Restoring pleasure: nutritional management of dysphagia